Summary
This economic evaluation of a randomised controlled trial (n=251) found no significant difference in costs or quality-adjusted life years between mitral valve repair and replacement for severe ischaemic mitral regurgitation at 2 years. Over 10 years, replacement showed marginal cost-effectiveness benefits through reduced cardiovascular readmission rates, though the uncertainty intervals were wide and the clinical and economic differences remained small and uncertain.
UK applicability
The findings may have limited direct applicability to UK practice, as the analysis was based on United States hospital costs and healthcare system structures. However, the comparative effectiveness framework and cost-effectiveness methodology could inform NHS commissioning decisions for similar cardiac interventions, subject to local cost adjustment.
Key measures
In-hospital costs, 2-year cumulative costs, quality-adjusted life years (QALYs), cardiovascular readmission rates, survival, incremental cost-effectiveness ratios
Outcomes reported
The study compared costs, quality-adjusted life years (QALYs), readmission rates, and survival outcomes between mitral valve repair and replacement for severe ischaemic mitral regurgitation over 2, 5, and 10-year time horizons.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.